| Name | Title | Contact Details |
|---|---|---|
Brooke Fern |
Director of Benefits and Wellness | Profile |
Nora Strom |
Director, Talent Acquisition Operations | Profile |
Exploring Opportunities in the Electric Vehicle Space.
The M+A name represents two powerful brands – Mountville and Andersen – with nearly a century of combined experience developing and manufacturing mats designed to make environments safer, cleaner, and more comfortable. In 1963, the late Emmett Hart, with his wife Nancy by his side, established Mountville Mills. A little over a decade later, in 1974, the late Walter Andersen established The Andersen Company. Throughout the years, the companies drove innovations in their respective markets; Mountville in the textile rental market, and Andersen in the janitorial/sanitary supply markets. Outstanding quality and customer service paved the way for future generations of Harts and Andersens to expand the business. In 1999, these flagship brands joined forces to become the largest mat manufacturer in the world, and in 2018 we made the union official with a name change to M+A Matting. For decades, weve been a symbol of quality and customer service. Were the driving force in the mat industry, developing the next generation of mats designed to provide superior safety, cleanliness, and comfort to workers and customers across the world. Our diverse product mix is a direct reflection of our diverse customers and end users who span virtually every industry – healthcare, hospitality, food service, retail, education, industrial, and commercial.
Purposeful Design is a Christian ministry that exists to help rebuild lives of individuals who have struggled with addiction, homelessness, incarceration and other obstacles; to equip them with valuable work skills; and to provide the gift of work (Genesis 2:15, Matthew 28:16-20, Ephesians 2:8-10).
AmeriVet Veterinary Partners is a company dedicated to supporting veterinary practices across the United States. Founded in 2016 and based in San Antonio, Texas, AmeriVet provides a range of business solutions that allow veterinary clinics to focus on animal care while benefiting from the companys resources and expertise. The services offered by AmeriVet include operational support, marketing strategies, professional training programs, human resources assistance, and financial management tools. These services are designed to enhance the efficiency and profitability of veterinary practices. AmeriVet operates on a partnership model, offering joint venture and full acquisition options that enable practice owners to maintain a stake in their business while accessing comprehensive support. With reported revenue of $205.5 million and significant funding, AmeriVet is recognized as a leading partner for veterinary clinics nationwide. The company has also been acknowledged as one of the top places to work in 2023, reflecting its commitment to a positive work environment for employees.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.